Published in Cancer Weekly, March 30th, 2010
"To evaluate available evidence regarding the efficacy and tolerability of IAD and assess its value in the treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.